Fig. 1From: Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trialTreatment study flowchart. A total of 113 participants were assessed for eligibility, 80 were recruited and randomly assigned to one of the groups. Among these patients, 36 in the amisulpride group, while 35 in the placebo group completed the 12-week trialBack to article page